The association between IL-1β overproduction by TET2 mutation and increased atherosclerosis is supported by the results of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial. The gene discussed is IL1B; the disease is atherosclerosis.